Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis

Parambir S. Dulai, Victoria Rai, Laura E. Raffals, Dana Lukin, David Hudesman, Gursimran S. Kochhar, Oriana M. Damas, Jenny S. Sauk, Alexander N. Levy, M. Anthony Sofia, Anne Tuskey, Parakkal Deepak, Andres J. Yarur, Anita Afzali, Ashwin N Ananthakrishnan, Raymond K. Cross, Stephen B. Hanauer, Corey A. Siegel
doi: https://doi.org/10.1101/2022.01.24.22269684
Parambir S. Dulai
1Division of Gastroenterology and Hepatology, Northwestern University, Chicago, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: parambir.dulai@northwestern.edu
Victoria Rai
2Department of Cellular and Molecular Physiology, Yale University, New Haven, CT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura E. Raffals
3Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dana Lukin
4Division of Gastroenterology and Hepatology, Weill Cornell Medicine, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Hudesman
5Division of Gastroenterology and Hepatology, New York University, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gursimran S. Kochhar
6Division of Gastroenterology and Hepatology, Alleghany Health, Pittsburgh, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oriana M. Damas
7Division of Gastroenterology and Hepatology, University of Miami Miller School of Medicine, Miami, FL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jenny S. Sauk
8Division of Gastroenterology and Hepatology, University of California Los Angeles, Los Angeles, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander N. Levy
9Division of Gastroenterology and Hepatology, Tufts Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Anthony Sofia
10Division of Gastroenterology and Hepatology, Oregon Health & Science University, Portland, OR
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Tuskey
11Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parakkal Deepak
12Division of Gastroenterology and Hepatology, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andres J. Yarur
13Division of Gastroenterology and Hepatology, Wisconsin University, Milwaukee, WI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita Afzali
14Division of Gastroenterology and Hepatology, Ohio State University, Columbus, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ashwin N Ananthakrishnan
15Division of Gastroenterology and Hepatology, Massachusetts General Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raymond K. Cross
16Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen B. Hanauer
1Division of Gastroenterology and Hepatology, Northwestern University, Chicago, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corey A. Siegel
17Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Limited guidance exists for the post-discharge care of ulcerative colitis (UC) patients hospitalized for moderate-severe flares.

Methods RAND methodology was used to establish appropriateness of inpatient and post-discharge steroid dosing, discharge criteria, follow-up, and post-discharge biologic or small molecule initiation. A literature review informed the panels voting, which occurred anonymously during two rounds before and after a moderated virtual session.

Results Methylprednisolone 40-60mg IV every 24 hours or hydrocortisone 300mg IV three times daily are appropriate for inpatient management, with methylprednisolone 40mg being appropriate if intolerant of higher doses. It is appropriate to discharge patients once rectal bleeding has resolved (Mayo sub score 0-1) and/or stool frequency has returned to baseline frequency and form (Mayo sub score 0-1). It is appropriate to discharge patients on 40mg of prednisone after observing patients for 24 hours in-hospital to ensure stability prior to discharge. For patients being discharged on steroids without in-hospital biologic or small molecule therapy initiation, it is appropriate to start anti-TNF therapy after discharge for anti-TNF naïve patients. For anti-TNF exposed patients it is appropriate to start vedolizumab or ustekinumab for all patients, and tofacitinib for those with a low risk of adverse events. It is appropriate to follow up patients clinically within 2 weeks, and with lower endoscopy within 4-6 months after discharge.

Conclusion We provide guidance on the inpatient and post-discharge management of UC patients hospitalized for moderate-severe flares.

WHAT IS KNOWN

  • Ulcerative colitis patients hospitalized for disease flares are a high-risk population

  • Guidance on evaluation and initial management during flares is provided, however, limited guidance exists on standardization of steroid management and post-discharge care

WHAT IS NEW HERE

  • Through a RAND Appropriateness Panel we provide guidance on the inpatient and post-discharge management of steroids, discharge criteria, post-discharge monitoring and management of biologics or small molecule therapies

  • These recommendations will help to bring uniformity to care for this high-risk population, and optimize outcomes in clinical practice

Competing Interest Statement

Parambir S. Dulai: Research support and/or consulting from Takeda, Janssen, Pfizer, Abbvie, Gilead, Lily, BMS, Novartis; stock options and board member for DigbiHealth; Licensing royalties from Precidiag. Victoria Rai: None Laura E. Raffals: Consulting from Janssen. Dana Lukin: Research support and/or consulting from Abbvie, Boehringer Ingelheim, BMS, Janssen, Palatin Technologies, Pfizer, Takeda; DSMB for WuXi Apptec; Scientific Advisory Board for PSI. David Hudesman: Research support from Jannsen and Pfizer; Consulting for Abbvie, BMS, Jannsen, Pfizer, Takeda. Gursimran S. Kochhar: Consulting for Lily. Oriana M. Damas: Research support and/or consulting from Pfizer. Jenny S. Sauk: Consulting or Speakers Bureau from Abbvie, CorEvitas, Pfizer, Prometheus. Alexander N. Levy: None Anthony Sofia: Consulting from Prometheus Biosciences. Anne Tuskey: Research support from AbbVie, Bristol Meyers Squibb, Eli Lily, Gilead Sciences, Parexal International/Takeda. Parakkal Deepak: Research support and/or consulting from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Scipher Medicine and CorEvitas, LLC Andres Yarur: Consultant Takeda, Bristol Myers Squibb, Prometheus Labs and Arena pharmaceuticals. Speaker bureau, Bristol Myers Squibb. Anita Afzali: Consulting and/or speaking for Abbvie, Janssen, Bristol Myers Squibb, Pfizer, Takeda, Eli Lilly, Gilead, Arena Pharmaceuticals, TLL Pharmaceuticals, DiaSorin. Ashwin Ananthakrishnan: Served on the scientific advisory boards for Abbvie, Ikena Oncology. Research funding from the Chleck Family Foundation, Crohns and Colitis Foundation, and National Institutes of Health. Raymond K. Cross: Research support and/or consulting from Abbvie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Prometheus, Samsung Bioepis, and Takeda Stephen B. Hanauer: Abbvie Consultant, Clinical Research (Institution), Speaker ; Allergan Consultant, Clinical Research (Institution) ;Amgen Consultant, Clinical Research (Institution); Arena Consultant, DSMB; Boehringer-Ingelheim Consultant, DSMB; BMS Consultant, DSMB; Celgene Consultant, Clinical Research (Institution); Celttrion Consultant; Genentech Consultant, Clinical Research, (Institution); Gilead Consultant, Clinical Research (Institution); GSK Consultant, Clinical Research (Institution); Janssen Consultant, Clinical Research (Institution), Speaker; Lilly Consultant, Clinical Research (Institution); Merck Consultant; Novartis Consultant, Clinical Research (Institution); Pfizer Consultant, Clinical Research (Institution), Speaker; Progenity Consultant; Prometheus Consultant, Clinical Research (Institution); Protagonist Consultant, DSMB; Receptos Consultant, Clinical Research (Institution), Salix (Consultant); Samsung Bioepis Consultant; Seres Therapeutics Consultant, Clinical Research (Institution); Takeda Consultant, Clinical Research (Institution), Speaker; UCB Consultant, Clinical Research (Institution), VHsquared Consultant. Corey A. Siegel: Consultant for Abbvie, BMS, Lilly, Janssen, Napo Pharmaceuticals, Pfizer, Prometheus, Takeda, Tellus Health. Speaker for CME activities for Abbvie, Janssen, Pfizer, Takeda. Grant support from Abbvie, Janssen, Pfizer and Takeda. Dr. Corey Siegel and Dr. Lori Siegel are co-founders of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.

Funding Statement

This study was funded by an NIDDK U34 planning grant (Dulai P; DK126626-01).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Guarantors of Article: Parambir S. Dulai, Victoria Rai, and Corey A. Siegel

  • Funding: This study was funded by an NIDDK U34 planning grant (Dulai P; DK126626-01). Dr. Dulai is supported by an American Gastroenterology Association Research Scholar Award. Dr. Deepak is supported by a Junior Faculty Development Award from the American College of Gastroenterology and IBD Plexus of the Crohn’s & Colitis Foundation.

  • Disclosures Parambir S. Dulai: Research support and/or consulting from Takeda, Janssen, Pfizer, Abbvie, Gilead, Lily, BMS, Novartis; stock options and board member for DigbiHealth; Licensing royalties from Precidiag.

    Victoria Rai: None

    Laura E. Raffals: Consulting from Janssen.

    Dana Lukin: Research support and/or consulting from Abbvie, Boehringer Ingelheim, BMS, Janssen, Palatin Technologies, Pfizer, Takeda; DSMB for WuXi Apptec; Scientific Advisory Board for PSI.

    David Hudesman: Research support from Jannsen and Pfizer; Consulting for Abbvie, BMS, Jannsen, Pfizer, Takeda.

    Gursimran S. Kochhar: Consulting for Lily.

    Oriana M. Damas: Research support and/or consulting from Pfizer.

    Jenny S. Sauk: Consulting/ Speaker’s Bureau from Abbvie, CorEvitas, Pfizer, Prometheus. Alexander N. Levy: None

    Anthony Sofia: Consulting from Prometheus Biosciences.

    Anne Tuskey: Research support from AbbVie, Bristol Meyers Squibb, Eli Lily, Gilead Sciences, Parexal International/Takeda.

    Parakkal Deepak: Research support and/or consulting from AbbVie, Arena Pharmaceuticals, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Pfizer, Prometheus Biosciences, Takeda Pharmaceuticals, Scipher Medicine and CorEvitas, LLC

    Andres Yarur: Consultant Takeda, Bristol Myers Squibb, Prometheus Labs and Arena pharmaceuticals. Speaker bureau, Bristol Myers Squibb.

    Anita Afzali: Consulting and/or speaking for Abbvie, Janssen, Bristol Myers Squibb, Pfizer, Takeda, Eli Lilly, Gilead, Arena Pharmaceuticals, TLL Pharmaceuticals, DiaSorin.

    Ashwin Ananthakrishnan: Served on the scientific advisory boards for Abbvie, Ikena Oncology. Research funding from the Chleck Family Foundation, Crohn’s and Colitis Foundation, and National Institutes of Health. Raymond K. Cross: Research support and/or consulting from Abbvie, Bristol Myers Squibb, Eli Lilly, Janssen, Pfizer, Prometheus, Samsung Bioepis, and Takeda

    Stephen B. Hanauer: Abbvie Consultant, Clinical Research (Institution), Speaker ; Allergan Consultant, Clinical Research (Institution) ;Amgen Consultant, Clinical Research (Institution); Arena Consultant, DSMB; Boehringer-Ingelheim Consultant, DSMB; BMS Consultant, DSMB; Celgene Consultant, Clinical Research (Institution); Celttrion Consultant; Genentech Consultant, Clinical Research, (Institution); Gilead Consultant, Clinical Research (Institution); GSK Consultant, Clinical Research (Institution); Janssen Consultant, Clinical Research (Institution), Speaker; Lilly Consultant, Clinical Research (Institution); Merck Consultant; Novartis Consultant, Clinical Research (Institution); Pfizer Consultant, Clinical Research (Institution), Speaker; Progenity Consultant; Prometheus Consultant, Clinical Research (Institution); Protagonist Consultant, DSMB; Receptos Consultant, Clinical Research (Institution), Salix (Consultant); Samsung Bioepis Consultant; Seres Therapeutics Consultant, Clinical Research (Institution); Takeda Consultant, Clinical Research (Institution), Speaker; UCB Consultant, Clinical Research (Institution), VHsquared Consultant.

    Corey A. Siegel: Consultant for Abbvie, BMS, Lilly, Janssen, Napo Pharmaceuticals, Pfizer, Prometheus, Takeda, Tellus Health. Speaker for CME activities for Abbvie, Janssen, Pfizer, Takeda. Grant support from Abbvie, Janssen, Pfizer and Takeda. Dr. Corey Siegel and Dr. Lori Siegel are co-founders of MiTest Health, LLC (software company). Technology developed by MiTest Health, LLC has been licensed to Takeda.

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted January 28, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis
Parambir S. Dulai, Victoria Rai, Laura E. Raffals, Dana Lukin, David Hudesman, Gursimran S. Kochhar, Oriana M. Damas, Jenny S. Sauk, Alexander N. Levy, M. Anthony Sofia, Anne Tuskey, Parakkal Deepak, Andres J. Yarur, Anita Afzali, Ashwin N Ananthakrishnan, Raymond K. Cross, Stephen B. Hanauer, Corey A. Siegel
medRxiv 2022.01.24.22269684; doi: https://doi.org/10.1101/2022.01.24.22269684
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis
Parambir S. Dulai, Victoria Rai, Laura E. Raffals, Dana Lukin, David Hudesman, Gursimran S. Kochhar, Oriana M. Damas, Jenny S. Sauk, Alexander N. Levy, M. Anthony Sofia, Anne Tuskey, Parakkal Deepak, Andres J. Yarur, Anita Afzali, Ashwin N Ananthakrishnan, Raymond K. Cross, Stephen B. Hanauer, Corey A. Siegel
medRxiv 2022.01.24.22269684; doi: https://doi.org/10.1101/2022.01.24.22269684

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Gastroenterology
Subject Areas
All Articles
  • Addiction Medicine (175)
  • Allergy and Immunology (423)
  • Anesthesia (97)
  • Cardiovascular Medicine (902)
  • Dentistry and Oral Medicine (172)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (408)
  • Epidemiology (8810)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1871)
  • Geriatric Medicine (179)
  • Health Economics (389)
  • Health Informatics (1294)
  • Health Policy (644)
  • Health Systems and Quality Improvement (495)
  • Hematology (207)
  • HIV/AIDS (397)
  • Infectious Diseases (except HIV/AIDS) (10593)
  • Intensive Care and Critical Care Medicine (565)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1770)
  • Nursing (105)
  • Nutrition (267)
  • Obstetrics and Gynecology (344)
  • Occupational and Environmental Health (461)
  • Oncology (968)
  • Ophthalmology (285)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (265)
  • Pediatrics (560)
  • Pharmacology and Therapeutics (266)
  • Primary Care Research (221)
  • Psychiatry and Clinical Psychology (1847)
  • Public and Global Health (3998)
  • Radiology and Imaging (657)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (538)
  • Rheumatology (216)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (167)
  • Surgery (199)
  • Toxicology (37)
  • Transplantation (107)
  • Urology (80)